Autopsy report · NCT01870609

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

“Interim analysis-DSMB stated good safety profile but lack of efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years 4 months before it stopped.
• 344 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Verastem, Inc.

Sponsor type

Industry

Conditions

Malignant Pleural Mesothelioma

Interventions

defactinib (VS-6063); Placebo

Participants

344

Sites

73

Countries

Australia, Belgium, Canada, France, Italy, Japan, Netherlands, New Zealand, Norway, Poland, South Africa, Spain and more

Trials that died the same way

• ATG Plus Low-dose PT-Cy for GVHD Prevention
  “DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.” (74% match in meaning)
• Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
  “The independent DSMB recommended that the study be stopped for futility following interim efficacy analysis.” (73% match in meaning)
• A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
  “The Data Safety Monitoring Board (DSMB) recommended study termination for slow accrual and futility.” (72% match in meaning)
• Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
  “The DSMB recommended that the study be stopped as a result of concerns regarding safety and intolerability and insufficient evidence of efficacy.” (72% match in meaning)
• Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
  “DSMB determined, due to higher than expected risk/safety concerns, study should be closed.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.